---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-25-000099"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:39:10.150639+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences Q2 2025 rev $160M (incl $143M one-time), net income breakeven; casdatifan Phase 3 trials initiated

## Summary
- Cash, cash equivalents & marketable securities: $927M at June 30, 2025 (Dec 31, 2024: $992M).
- Q2 2025 revenue $160M vs $39M YoY, driven by $143M cumulative catch-up from etrumadenant program pause.
- R&D expenses $139M (vs $115M Q2 2024); CMC costs expected elevated through Q3, then decline from Q4.
- PEAK-1 (Phase 3 casdatifan + cabozantinib) and eVOLVE-RCC02 (Phase 1b/3 with AstraZeneca) initiated in ccRCC.
- Quemliclustat granted FDA Orphan Drug Designation for pancreatic cancer; PRISM-1 enrollment completion expected Q3 2025.

## SEC filing metadata
- accession: 0001724521-25-000099
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000099/0001724521-25-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452125000099/rcus-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-25-000099
- JSON: https://secwatch.observer/filing/0001724521-25-000099.json
- Plain text: https://secwatch.observer/filing/0001724521-25-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.